Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=25 Randomized Single-blind Prevention

PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation

Vitiligo

Bottom Line

View on ClinicalTrials.gov: NCT03933774 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tretinoin 0.05% cream (Drug); Placebo cream (Drug)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
The Catholic University of Korea
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
The Degree of Hyperpigmentation at 12 Weeks		 56.8; 57.6; 51.0; 54.3 0.002 sig
SECONDARY
Number of Participants Who Showed ≥75% Repigmentation		 8; 9; 8; 9 0.479

Summary

A randomized controlled split-face pilot study was planned to investigate the preventive effect of tretinoin 0.05% cream on hyperpigmentation during phototherapy in patients with vitiligo.

Eligibility Criteria

Inclusion Criteria

  • Age: older than 19
  • A patient with stable non-segmental vitiligo
  • A patient with symmetrical vitiligo lesions on face
  • A patient with the willingness to comply with the study protocol during the study period and capable of complying with it.
  • A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages.

Exclusion Criteria

  • Age: lower than 20
  • A pregnant or lactating patient
  • A patient with active or spreading vitiligo
  • A patient who cannot understand the study or who does not sign the informed consent
  • Women of childbearing potential not using an effective method of contraception properly
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03933774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search